Addex Therapeutics Ltd (ADXN) AI Stock Analysis

Addex Therapeutics Ltd is a developmental-stage biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule pharmaceutical products targeting central nervous system (CNS) disorders. Headquartered in Geneva, Switzerland, the company specializes in oral small molecule allosteric modulators of G-protein coupled receptors. Its lead development programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 targeting epilepsy and other CNS indications, and a GABAB positive allosteric modulator for addiction treatment. Addex advances these programs through partnerships and licensing agreements with Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot-Marie-Tooth Association, employing 3 people.

Addex's revenue fell from $2.9M in FY2021 to $1.4M in FY2022, before rising 13.4% to $1.6M in FY2023. Revenue then declined 74.9% to $404,102 in FY2024 and dropped 92.6% to $29,972 in FY2025, marking a 5-year revenue CAGR of -61.6% from FY2020 to FY2025. Net income was -$15.4M in FY2021, -$20.8M in FY2022, and -$10.6M in FY2023. Although FY2024 generated net income of $7.1M, net income swung back to -$6.7M in FY2025 with an operating margin of -9390.8%. In the trailing twelve months ended June 30, 2026, revenue stood at $83,069, with quarterly revenue falling 72.7% year-over-year.

As of June 30, 2026, Addex held $767,328 in cash and short-term investments and $77,495 in total debt, resulting in net cash of $689,833. Shareholders' equity was $1.9M alongside total assets of $3.5M, yielding a current ratio of 0.76 and a debt-to-equity ratio of 0.04. The company continues to burn cash, reporting operating cash flow and free cash flow of -$2.1M in FY2025. Cash use that year included $28,850 in share buybacks, while the share count increased 401.7% over the 5-year period.

Addex has a market capitalization of $4.8M and an enterprise value of $3.4M. Its price-to-sales multiple is 58.2x, significantly higher than the 4.1x median of its US-listed Healthcare peers. The company trades at a price-to-book ratio of 1.1x and an EV-to-revenue multiple of 92.8x. Over the past year, ADXN dropped 67.6% while the S&P 500 returned 16.8%. Over a 5-year period, ADXN shares fell 98.4%, compared to an 83.0% gain for the S&P 500.

Analysts have established a mean price target of $30.00 for ADXN, representing 987.0% upside relative to its last close of $2.76 on October 16, 2026. For the next fiscal year, consensus estimates project revenue of $1.5M with 0.0% growth and an EPS estimate of $0.00. The company recorded 0 EPS beats over the last 4 quarters. The next earnings release date is scheduled for December 3, 2026.

This page is an AI-written research summary of Addex Therapeutics Ltd (ADXN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ADXN income statement, ADXN balance sheet, ADXN key metrics, ADXN analyst forecast, ADXN chart. See the ADXN stock overview for the latest quote and news.